{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MRS&page=20", "query": { "intervention": "MRS", "page": 20 }, "page_size": 10 }, "pagination": { "page": 20, "page_size": 10, "total_count": 1916, "total_pages": 192, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MRS&page=21&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MRS&page=19&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-26T17:29:29.886Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07128680", "title": "Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Clear Cell Renal Cell Carcinoma", "Advanced Sarcomatoid Renal Cell Carcinoma", "Metastatic Clear Cell Renal Cell Carcinoma", "Metastatic Sarcomatoid Renal Cell Carcinoma", "Stage III Renal Cell Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Faecalibacterium prausnitzii-containing Bacterial Strain Formulation EXL01", "type": "DIETARY_SUPPLEMENT" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DIETARY_SUPPLEMENT", "BIOLOGICAL" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2026-03-23", "completion_date": "2028-08-25", "has_results": false, "last_update_posted_date": "2026-07-16", "last_synced_at": "2026-10-26T17:29:29.886Z", "location_count": 2, "location_summary": "Duarte, California • Irvine, California", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07128680" }, { "nct_id": "NCT07215910", "title": "Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Astrocytoma, IDH-Mutant, Grade 3" ], "interventions": [ { "name": "Intensity-Modulated Radiation Therapy", "type": "RADIATION" }, { "name": "Volume Modulated Arc Therapy", "type": "RADIATION" }, { "name": "Pencil Beam Scanning", "type": "RADIATION" }, { "name": "Intensity-Modulated Proton Therapy", "type": "PROCEDURE" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Vorasidenib", "type": "DRUG" }, { "name": "Placebo Administration", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "RADIATION", "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 408, "start_date": "2026-06-24", "completion_date": "2040-01", "has_results": false, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-10-26T17:29:29.886Z", "location_count": 152, "location_summary": "Bakersfield, California • Duarte, California • Dublin, California + 119 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Dublin", "state": "California" }, { "city": "Fremont", "state": "California" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07215910" }, { "nct_id": "NCT05001880", "title": "Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Peritoneal Malignant Mesothelioma" ], "interventions": [ { "name": "Atezolizumab", "type": "BIOLOGICAL" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cytoreductive Surgery", "type": "PROCEDURE" }, { "name": "Hyperthermic Intraperitoneal Chemotherapy", "type": "DRUG" }, { "name": "Pemetrexed Disodium", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2022-03-22", "completion_date": "2027-08-01", "has_results": false, "last_update_posted_date": "2026-10-26", "last_synced_at": "2026-10-26T17:29:29.886Z", "location_count": 41, "location_summary": "Phoenix, Arizona • Chicago, Illinois • Danville, Illinois + 31 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Danville", "state": "Illinois" }, { "city": "Effingham", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05001880" }, { "nct_id": "NCT07504588", "title": "Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma", "Recurrent Platinum-Sensitive Fallopian Tube High Grade Serous Adenocarcinoma", "Recurrent Platinum-Sensitive Ovarian High Grade Endometrioid Adenocarcinoma", "Recurrent Platinum-Sensitive Ovarian High Grade Serous Adenocarcinoma", "Recurrent Platinum-Sensitive Primary Peritoneal Endometrioid Adenocarcinoma", "Recurrent Platinum-Sensitive Primary Peritoneal High Grade Serous Adenocarcinoma" ], "interventions": [ { "name": "Anti-VEGF Monoclonal Antibody", "type": "BIOLOGICAL" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Pegylated Liposomal Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Sacituzumab Govitecan", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 87, "start_date": "2026-09-24", "completion_date": "2029-04-12", "has_results": false, "last_update_posted_date": "2026-10-20", "last_synced_at": "2026-10-26T17:29:29.886Z", "location_count": 13, "location_summary": "Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 9 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Coeur d'Alene", "state": "Idaho" }, { "city": "Post Falls", "state": "Idaho" } ], "official_url": "https://clinicaltrials.gov/study/NCT07504588" }, { "nct_id": "NCT03418623", "title": "Effect of GET73 on MRS Measures of Central Glutamate and GABA in Individuals With Alcohol Use Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Alcohol Use Disorder" ], "interventions": [ { "name": "GET73", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Laboratorio Farmaceutico Ct S.r.l.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "21 Years to 40 Years" }, "enrollment_count": 24, "start_date": "2018-03-08", "completion_date": "2020-03-13", "has_results": false, "last_update_posted_date": "2020-10-08", "last_synced_at": "2026-10-26T17:29:29.886Z", "location_count": 1, "location_summary": "Charleston, South Carolina", "locations": [ { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03418623" }, { "nct_id": "NCT05061004", "title": "Cephea Early Feasibility Study", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Mitral Regurgitation" ], "interventions": [ { "name": "Cephea Mitral Valve System", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Abbott Medical Devices", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 90, "start_date": "2022-04-28", "completion_date": "2031-03-01", "has_results": false, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-10-26T17:29:29.886Z", "location_count": 20, "location_summary": "Phoenix, Arizona • Los Angeles, California • Sacramento, California + 15 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Thousand Oaks", "state": "California" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05061004" }, { "nct_id": "NCT06447987", "title": "Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Acute Lymphoblastic Leukemia", "Refractory Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes", "type": "BIOLOGICAL" }, { "name": "Cetuximab", "type": "BIOLOGICAL" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Echocardiography", "type": "PROCEDURE" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Leukapheresis", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "DRUG" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2024-11-06", "completion_date": "2026-12-05", "has_results": false, "last_update_posted_date": "2026-06-05", "last_synced_at": "2026-10-26T17:29:29.886Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06447987" }, { "nct_id": "NCT00662506", "title": "Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adult Giant Cell Glioblastoma", "Adult Glioblastoma", "Adult Gliosarcoma" ], "interventions": [ { "name": "Cediranib Maleate", "type": "DRUG" }, { "name": "Diffusion Tensor Imaging", "type": "PROCEDURE" }, { "name": "Diffusion Weighted Imaging", "type": "PROCEDURE" }, { "name": "Dynamic Contrast-Enhanced Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Fludeoxyglucose F-18", "type": "RADIATION" }, { "name": "Intensity-Modulated Radiation Therapy", "type": "RADIATION" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Perfusion Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2008-04", "completion_date": "2014-04", "has_results": false, "last_update_posted_date": "2023-06-06", "last_synced_at": "2026-10-26T17:29:29.886Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00662506" }, { "nct_id": "NCT00085293", "title": "Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Thyroid Cancer", "Stage IVA Follicular Thyroid Cancer", "Stage IVA Papillary Thyroid Cancer", "Stage IVB Follicular Thyroid Cancer", "Stage IVB Papillary Thyroid Cancer", "Stage IVC Follicular Thyroid Cancer", "Stage IVC Papillary Thyroid Cancer" ], "interventions": [ { "name": "Decitabine", "type": "DRUG" }, { "name": "Iodine I 131", "type": "RADIATION" }, { "name": "Recombinant thyrotropin alfa", "type": "BIOLOGICAL" }, { "name": "Fludeoxyglucose F 18", "type": "RADIATION" }, { "name": "Positron emission tomography", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2004-05", "completion_date": "2014-05", "has_results": true, "last_update_posted_date": "2018-11-29", "last_synced_at": "2026-10-26T17:29:29.886Z", "location_count": 3, "location_summary": "Aurora, Colorado • Columbus, Ohio • Houston, Texas", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00085293" }, { "nct_id": "NCT03201458", "title": "Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gallbladder Carcinoma", "Metastatic Cholangiocarcinoma", "Stage III Intrahepatic Cholangiocarcinoma AJCC v8", "Stage IV Intrahepatic Cholangiocarcinoma AJCC v8", "Unresectable Cholangiocarcinoma" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cobimetinib", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 86, "start_date": "2018-02-08", "completion_date": "2024-02-19", "has_results": true, "last_update_posted_date": "2024-04-05", "last_synced_at": "2026-10-26T17:29:29.886Z", "location_count": 41, "location_summary": "Duarte, California • Sacramento, California • South Pasadena, California + 31 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "South Pasadena", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Derby", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03201458" } ] }